Anti-huCD20 antibody therapy for antibody-mediated rejection of renal allografts in a mouse model

American Journal of Transplantation

Volumn 15, Issue 5, 2015, Pages 1192-1204

  Abe, T ^a,b   Ishii, D ^a,c   Gorbacheva, V ^a   Kohei, N ^a   Tsuda, H ^a   Tanaka, T ^a   Dvorina, N ^a   Nonomura, N ^b   Takahara, S ^b   Valujskikh, A ^a   Baldwin, W M ^a,d   Fairchild, R L ^a,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

alloantibody; B cell specific; chronic; fusion proteins and monoclonal antibodies; immunosuppressant; kidney disease: immune inflammatory; rejection; rejection: antibody mediated (ABMR)

Indexed keywords

COMPLEMENT COMPONENT C4D; CREATININE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RITUXIMAB; ANTIBODY; CCR5 PROTEIN, MOUSE; CD20 ANTIGEN; CHEMOKINE RECEPTOR CCR5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SECRETING CELL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GRAFT SURVIVAL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROPHYLAXIS; ALLOGRAFT; ALLOTRANSPLANTATION; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; FIBROSIS; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETICS; GRAFT REJECTION; HUMAN; IMMUNOLOGY; MALE; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY; TIME FACTOR; TRANSGENIC MOUSE;

ALLOGRAFTS; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; ANTIGENS, CD20; CREATININE; DISEASE MODELS, ANIMAL; FIBROSIS; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY TRANSPLANTATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; RECEPTORS, CCR5; RENAL INSUFFICIENCY; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84928084455     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13150     Document Type: Article

References (27)

1. Colvin RB, Smith RN,. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807-817.
2. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria-an addition ot the Banff '97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
3. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033-1041.
4. Uber WE, Self SE, van Bakel AB, Pereira NL,. Acute antibody-mediated rejection following heart trasnplantation. Am J Transplant 2007; 7: 2064-2074.
5. Albrecht EA, Chinnaiyan AM, Varambally S, et al. C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol 2004; 164: 849-859.
6. Gloor J, Cosio F, Lager DJ, Stegall MD,. The spectrum of antibody-mediated renal allograft injury: Implications for treatment. Am J Transplant 2008; 8: 1367-1373.
7. Saadl S, Holzknecht RA, Patte CP, Platt JL,. Endothelial cell activation by pore-forming structures: Pivotal role for interleukin-1a. Circulation 2000; 101: 1867-1873.
8. Saadl S, Platt JL,. Humoral rejection and endothelial cell activation. Xenotransplantation 2002; 9: 239-241.
9. Taflin C, Charron D, Glotz D, Mooney N,. Immunological function of the endothelial cell within the setting of organ transplantation. Immunol Lett 2011; 139: 1-6.
10. Zhang X, Reed EF,. Effect of antibodies on endothelium. Am J Transplant 2009; 9: 2459-2465.
11. Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC,. Regulation by complement C3a, C5aq anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003; 17: 1003-1014.
12. Terasaki P, Mizutani K,. Antibody mediated rejection: Update 2006. Clin J Am Soc Nephrol 2006; 1: 400-403.
13. Trpkov K, Campbell P, Pazderka F, Cockfield S, Solez K, Halloran PF,. Pathologic features of acute renal allograft rejection associated with donor-specific antibody. Analysis using the Banff grading schema. Transplantation 1996; 61: 1586-1592.
14. Regele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371-2380.
15. Loupy A, Hill GS, Jordan SC,. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012; 8: 348-357.
16. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major casue of late kidny transplant failure. Am J Transplant 2009; 9: 2520-2531.
17. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 389-399.
18. -/- recipients. Am J Transplant 2008; 8: 557-566.
19. Hattori Y, Bucy RP, Kubota Y, Baldwin WM, III.; Fairchild RL,. Antibody-mediated rejection of single class I MHC-disparate cardiac allografts. Am J Transplant 2012; 12: 2017-2028.
20. Nozaki T, Amano H, Bickerstaff A, et al. Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients. J Immunol 2007; 179: 5238-5245.
21. Zhang Z, Schlachta C, Duff J, Stiller C, Grant D, Zhong R,. Improved techniques for kidney transplantation in mice. Microsurgery 1995; 16: 103-109.
22. Han WR, Murray-Segal LJ, Mottram PL,. Modified technique for kidney transplantatiion in mice. Microsurgery 1999; 19: 272-274.
23. Murata K, Fox-Talbot K, Qian Z, et al. Synergistic dpeosition of C4d by complement-activating and non-activating antibodies in cardiac transplants. Am J Tranasplant 2007; 7: 2605-2614.
24. Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttransplant prophylactic IVIg/anti-CD20/plasmaphoresis in kidney recipients with preformed donor-specific antibodies: A pilot study. Transplantation 2010; 89: 1403-1410.
25. Kohei N, Hirai T, Omoto K, Ishida K, Tanabe K,. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12: 469-476.
26. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting report: Differential diagnosis of chronic allograft injury ad elimination of chronic allograft nephropathy ("CAN"). Am J Transplant 2007; 7: 518-526.
27. Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012; 209: 1001-1010.